P-662 Embryo ploidy rates following PPOS or GnRH antagonist protocol. A prospective study with repeated ovarian stimulation

Abstract Study question Is there any difference in embryo ploidy rates following progesterone primed ovarian stimulation (PPOS) using micronized or GnRH antagonist protocol? Summary answer Pituitary downregulation with a PPOS protocol results comparable number of euploid blastocysts protocol. What is known already Although the consider by most gold standard for controlling LH surge during IVF/ICSI, progesterone-primed protocols are being increasing used freeze-all protocols. Still, despite promising protocols, an early randomized trial reported potentially lower live births recipients oocytes resulting medroxyprogesterone acetate as compared The scope current prospective study was to investigate whether equivalent blastocyst euploidy design, size, duration In this study, performed between September 2019 January 2022, 44 women underwent two consecutive (OS) within period 6 months oral progesterone. Participants/materials, setting, methods Overall, OS cycles identical fixed dose rFSH (225 300 IU) both cycles. Downregulation 1st use flexible and consecutively, after washout one month, control from day 1. After completion cycles, all generated genetic analysis aneuploidy screening (PGT-A). Main role chance Comparisons did not reveal differences neither gonadotrophins dose. Hormonal profile on trigger revealed statistically significant tested hormones except FSH: significantly higher serum E2 levels, more elevated levels Progesterone respectively. resulted (10.27± 5.84 versus 12.68± 8.09), (DBM -2.4 [95% CI -4.1; -0.73]), MIIs (7.34±4.15 9.09± 6.12), -1.8 -3.1; -0.43]), 2PNs (5.66±3.35 7.14± 4.99), -1.5 -2.6.1; -0.32]) Nevertheless, no were observed regarding mean (2.84±2.12 2.91±2.11), -0.07 -0.67; 0.53]) biopsied (2.86±2.15 2.93±2.16), -0.70; 0.56]). Finally, primary outcome, embryos 0.86 ± 0.90 vs. 1.00 1.12 comparison GnRh antagonist. Limitations, reasons caution powered detect terms pregnancy outcomes. Additionally, per randomisation, first cycle always 2nd month between. Wider implications findings provides evidence that may result This imply case protocol, clinicians safely patients could benefit advantages (cost administration). Trial registration NCT04108039